TY - JOUR
T1 - How do psychiatrists choose among different antipsychotics?
AU - Hamann, Johannes
AU - Kolbe, Grit
AU - Cohen, Rudolf
AU - Leucht, Stefan
AU - Kissling, Werner
N1 - Funding Information:
Acknowledgements The authors would like to thank all participating physicians for their help, Bernadette Langer for performing the interviews, Hanna Förster for coding the interviews and Ulrich Hoffrage for his advice. This work was funded by unrestricted grants from Sanofi Synthelabo, Berlin, Germany and Astra Zeneca, Wedel, Germany.
PY - 2005/12
Y1 - 2005/12
N2 - Objective: We attempted to determine the decision rules psychiatrists use in the choice of antipsychotic drugs for inpatients with schizophrenia. Methods: Interviews were conducted with 50 hospital psychiatrists in Southern Germany. Each physician was interviewed with respect to the reasons for his antipsychotic drug choice in the cases of three patients with a diagnosis of schizophrenia. Interviews were audiotaped and subsequently analyzed using a standardized coding scheme. Results: The clinical decision rules identified are highly complex, with a mean of eight categories cited per patient. Categories named included the patient's past treatment response, side effects, intended route of administration and co-morbidities. Moreover, psychiatrists strongly take the patient's target symptoms and the assumed efficacy of certain compounds into account in their choice of medication. Conclusion: Psychiatrists' explanations for their antipsychotic drug choice seem for the most part reasonable and overlap substantially with drug-choice algorithms of clinical guidelines. However, psychiatrists additionally use indicators that-in their view-might predict treatment response. For these indicators, which are derived from personal experience, it is still unclear whether they are valid and simply have not yet been proven in clinical trials or whether they merely represent unfounded assumptions on the part of the doctors.
AB - Objective: We attempted to determine the decision rules psychiatrists use in the choice of antipsychotic drugs for inpatients with schizophrenia. Methods: Interviews were conducted with 50 hospital psychiatrists in Southern Germany. Each physician was interviewed with respect to the reasons for his antipsychotic drug choice in the cases of three patients with a diagnosis of schizophrenia. Interviews were audiotaped and subsequently analyzed using a standardized coding scheme. Results: The clinical decision rules identified are highly complex, with a mean of eight categories cited per patient. Categories named included the patient's past treatment response, side effects, intended route of administration and co-morbidities. Moreover, psychiatrists strongly take the patient's target symptoms and the assumed efficacy of certain compounds into account in their choice of medication. Conclusion: Psychiatrists' explanations for their antipsychotic drug choice seem for the most part reasonable and overlap substantially with drug-choice algorithms of clinical guidelines. However, psychiatrists additionally use indicators that-in their view-might predict treatment response. For these indicators, which are derived from personal experience, it is still unclear whether they are valid and simply have not yet been proven in clinical trials or whether they merely represent unfounded assumptions on the part of the doctors.
UR - http://www.scopus.com/inward/record.url?scp=28344437241&partnerID=8YFLogxK
U2 - 10.1007/s00228-005-0041-7
DO - 10.1007/s00228-005-0041-7
M3 - Article
C2 - 16235042
AN - SCOPUS:28344437241
SN - 0031-6970
VL - 61
SP - 851
EP - 854
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 11
ER -